BR0015846A - Método para a produção de um vìrus e/ou proteìnas virais diferentes de adenovìrus ou proteìnas adenovirais, uso de uma célula humana, vìrus ou proteìna viral para uso em uma vacina obtenìvel por meio dos citados métodos e uso, célula humana kit para determinar a atividade de uma protease em uma amostra, uso de uma proteìna viral ou um vìrus, método para concentrar vìrus influenza em condições capazes de, pelo menos em parte,preservar a capacidade de infecção do vìrus, e, vìrus influenza infeccioso ou seus derivados. - Google Patents

Método para a produção de um vìrus e/ou proteìnas virais diferentes de adenovìrus ou proteìnas adenovirais, uso de uma célula humana, vìrus ou proteìna viral para uso em uma vacina obtenìvel por meio dos citados métodos e uso, célula humana kit para determinar a atividade de uma protease em uma amostra, uso de uma proteìna viral ou um vìrus, método para concentrar vìrus influenza em condições capazes de, pelo menos em parte,preservar a capacidade de infecção do vìrus, e, vìrus influenza infeccioso ou seus derivados.

Info

Publication number
BR0015846A
BR0015846A BR0015846-1A BR0015846A BR0015846A BR 0015846 A BR0015846 A BR 0015846A BR 0015846 A BR0015846 A BR 0015846A BR 0015846 A BR0015846 A BR 0015846A
Authority
BR
Brazil
Prior art keywords
virus
viral protein
human cell
production
influenza viruses
Prior art date
Application number
BR0015846-1A
Other languages
English (en)
Other versions
BRPI0015846B1 (pt
BRPI0015846B8 (pt
Inventor
Maria Grazia Capri
Alphonsus Gerardus C Uytdehaag
Govert Johan Schouten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0015846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of BRPI0015846B1 publication Critical patent/BRPI0015846B1/pt
Publication of BR0015846A publication Critical patent/BR0015846A/pt
Publication of BRPI0015846B8 publication Critical patent/BRPI0015846B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA A PRODUçãO DE UM VìRUS E/OU PROTEìNAS VIRAIS DIFERENTES DE ADENOVìRUS OU PROTEìNAS ADENOVIRAIS, USO DE UMA CéLULA HUMANA, VìRUS OU PROTEìNA VIRAL PARA USO EM UMA VACINA OBTENìVEL POR MEIO DOS CITADOS MéTODO E USO, CéLULA HUMANA KIT PARA DETERMINAR A ATIVIDADE DE UMA PROTEASE EM UMA AMOSTRA, USO DE UMA PROTEìNA VIRAL OU UM VìRUS, MéTODO PARA CONCENTRAR VìRUS INFLUENZA EM CONDIçõES CAPAZES DE, PELO MENOS EM PARTE, PRESERVAR A CAPACIDADE DE INFECçãO DO VIRUS, E, VIRUS INFLUENZA INFECCIOSO OU SEUS DERIVADOS". Proporciona-se meios e métodos inéditos para a produção de vírus mamíferos, compreendendo infectar uma cultura de células humana imortalizadas com o vírus, incubar a cultura infectada com vírus para propagar o vírus em condições que permitem o desenvolvimento do vírus, e formar um meio contendo virus e remover o meio contendo vírus. Os vírus podem ser coletados e usados para a produção de vacinas. Vantagens células humanas da presente invenção podem ser cultivadas em condições definidas isentas de soro, e as células apresentam capacidade aperfeiçoada para propagar vírus. Em particular, proporciona-se métodos para produzir, em células humanas cultivadas, vírus Influenza e vacinas derivadas dos mesmos. Este método elimina a necessidade de se usar embriões inteiros de galinhas para a produção de vacinas de Influenza. O método proporciona também a remoção contínua ou em bateladas de meios de cultura. Assim, a presente invenção permite a produção contínua e em grande escala de vírus com alta concentração.
BR0015846-1A 1999-11-26 2000-11-24 Método para a produção de um vìrus e/ou proteìnas virais diferentes de adenovìrus ou proteìnas adenovirais, uso de uma célula humana, vìrus ou proteìna viral para uso em uma vacina obtenìvel por meio dos citados métodos e uso, célula humana kit para determinar a atividade de uma protease em uma amostra, uso de uma proteìna viral ou um vìrus, método para concentrar vìrus influenza em condições capazes de, pelo menos em parte,preservar a capacidade de infecção do vìrus, e, vìrus influenza infeccioso ou seus derivados. BR0015846A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99203983.4 1999-11-26
EP99203983A EP1103610A1 (en) 1999-11-26 1999-11-26 Production of vaccines from immortalised mammalian cell lines
PCT/NL2000/000862 WO2001038362A2 (en) 1999-11-26 2000-11-24 Production of vaccines

Publications (3)

Publication Number Publication Date
BRPI0015846B1 BRPI0015846B1 (pt) 2001-05-31
BR0015846A true BR0015846A (pt) 2002-07-16
BRPI0015846B8 BRPI0015846B8 (pt) 2021-05-25

Family

ID=8240914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015846-1A BR0015846A (pt) 1999-11-26 2000-11-24 Método para a produção de um vìrus e/ou proteìnas virais diferentes de adenovìrus ou proteìnas adenovirais, uso de uma célula humana, vìrus ou proteìna viral para uso em uma vacina obtenìvel por meio dos citados métodos e uso, célula humana kit para determinar a atividade de uma protease em uma amostra, uso de uma proteìna viral ou um vìrus, método para concentrar vìrus influenza em condições capazes de, pelo menos em parte,preservar a capacidade de infecção do vìrus, e, vìrus influenza infeccioso ou seus derivados.

Country Status (21)

Country Link
EP (3) EP1103610A1 (pt)
JP (1) JP4331432B2 (pt)
KR (2) KR20060107868A (pt)
CN (1) CN1306033C (pt)
AT (1) ATE286537T1 (pt)
AU (2) AU775966B2 (pt)
BR (1) BR0015846A (pt)
CA (1) CA2392653C (pt)
DE (1) DE60017234T3 (pt)
DK (1) DK1108787T4 (pt)
EA (1) EA006136B1 (pt)
ES (1) ES2235770T5 (pt)
HK (1) HK1057236A1 (pt)
IL (2) IL149788A0 (pt)
MX (1) MXPA02005237A (pt)
NO (1) NO333527B1 (pt)
NZ (1) NZ527942A (pt)
PT (1) PT1108787E (pt)
SI (1) SI1108787T2 (pt)
WO (1) WO2001038362A2 (pt)
ZA (1) ZA200204078B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
WO2003048197A1 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
IL157003A0 (en) 2001-01-19 2004-02-08 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
DE60226896D1 (de) * 2001-12-17 2008-07-10 Crucell Holland Bv Herstellung von f(ab')2 fragmenten in saügetierzelle
CN1646684B (zh) 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE453708T1 (de) * 2002-11-08 2010-01-15 Crucell Holland Bv Impfstoff gegen west nile virus
EP1590450A2 (en) * 2002-12-20 2005-11-02 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CN101328473B (zh) * 2003-05-09 2012-05-02 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
DK1780269T3 (da) 2004-02-23 2009-10-12 Crucell Holland Bv Virusrensningsmetoder
EP2540815A1 (en) * 2004-03-05 2013-01-02 DSM IP Assets B.V. Perfusion cell culture
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
EP2811027A1 (en) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for RSV and PIV vaccines
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
JP2006090864A (ja) * 2004-09-24 2006-04-06 Denka Seiken Co Ltd ワクチン中の特定成分の含量を求める方法
EP2573186A1 (en) 2004-12-08 2013-03-27 MedImmune, LLC Methods of producing influenza vaccine compositions
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US7888102B2 (en) 2005-07-22 2011-02-15 Crucell Holland B.V. Cell line for producing coronaviruses
PT2301572E (pt) 2005-11-01 2014-12-22 Novartis Vaccines & Diagnostic Vacinas virais derivadas de células com níveis baixos de adn celular residual
PL2343362T3 (pl) 2006-07-14 2016-11-30 Udoskonalony sposób hodowania komórek
ES2618490T3 (es) * 2007-07-03 2017-06-21 Transgene Sa Estirpes celulares aviares inmortalizadas
EP2222694B1 (en) * 2007-12-13 2014-01-15 Roche Diagnostics GmbH Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
EA201071086A1 (ru) * 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
US8163523B2 (en) 2008-06-11 2012-04-24 Flugen, Inc. Cell-based systems for producing influenza vaccines
AU2009272857B2 (en) * 2008-07-15 2015-06-18 Crucell Holland B.V. Scalable process for culturing PER.C6 cells and producing products therefrom
EP2168987A1 (en) * 2008-09-22 2010-03-31 Mucosis B.V. Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions
WO2010052214A2 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
NZ596880A (en) * 2009-07-16 2013-10-25 Crucell Holland Bv Production of polio virus at high titers for vaccine production
WO2011139717A1 (en) 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
MX363307B (es) 2010-10-11 2019-03-20 Novartis Ag Star Plataformas para suministro de antigenos.
HUE043879T2 (hu) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa RSV-immunizálási rend
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
CN102526720B (zh) * 2012-01-11 2013-12-11 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒疫苗的制备方法
RU2599496C2 (ru) 2012-03-06 2016-10-10 Круселл Холланд Б.В. Улучшенная вакцинация против гриппа
CN102631673A (zh) * 2012-04-17 2012-08-15 金宇保灵生物药品有限公司 口蹄疫疫苗浓缩纯化方法
TWI656839B (zh) 2013-03-15 2019-04-21 健臻公司 高密度細胞儲存方法
RU2723129C2 (ru) 2014-09-18 2020-06-08 Джензим Корпорейшн Способы создания банков клеток со сверхвысокой плотностью
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
IL252917B2 (en) 2014-12-17 2023-10-01 Fundacion Para La Investig Medica Aplicada Vectors and vectors for gene therapy for use in the treatment of Wilson's disease
JP6956635B2 (ja) 2014-12-17 2021-11-02 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病及び他の状態の処置に使用するための核酸構築物及び遺伝子治療ベクター
CN108027371B (zh) * 2015-07-07 2020-08-18 思齐乐 流感效力试验
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
BR112020008652A2 (pt) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
KR20200015323A (ko) 2018-08-03 2020-02-12 에릭스바이오(주) 바이러스 치료 장치 또는 백신 제조 장치
BR112021006881A2 (pt) 2018-10-12 2021-07-13 Vivet Therapeutics transgene otimizado por códon para o tratamento de colestase intra-hepática familiar progressiva tipo 3 (pfic3)
CN113302290A (zh) 2018-11-16 2021-08-24 编码治疗公司 治疗威尔逊氏病的组合物和方法
CA3137652A1 (en) 2019-05-08 2020-11-12 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
AR123168A1 (es) 2020-08-06 2022-11-02 Fundacion Para La Investig Medica Aplicada Partículas virales para uso en el tratamiento de tauopatías tales como enfermedades de alzheimer mediante terapia génica
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
AR123756A1 (es) 2020-10-09 2023-01-11 UCB Biopharma SRL Construcciones de ácidos nucléicos, vectores virales y partículas virales
AU2022378524A1 (en) 2021-10-28 2024-05-02 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547779A (en) * 1968-12-18 1970-12-15 Merck & Co Inc Process for producing purified concentrated influenza virus
US5192539A (en) * 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines

Also Published As

Publication number Publication date
DE60017234T2 (de) 2005-12-08
PT1108787E (pt) 2005-04-29
AU2004203642A1 (en) 2004-09-02
DK1108787T4 (da) 2009-04-14
KR20020064910A (ko) 2002-08-10
IL149788A0 (en) 2002-11-10
KR100683374B1 (ko) 2007-02-15
SI1108787T1 (en) 2005-06-30
BRPI0015846B1 (pt) 2001-05-31
CN1306033C (zh) 2007-03-21
MXPA02005237A (es) 2003-09-22
JP2003516733A (ja) 2003-05-20
EP1514937A1 (en) 2005-03-16
CA2392653A1 (en) 2001-05-31
EP1108787B1 (en) 2005-01-05
EP1108787A3 (en) 2001-08-29
DE60017234D1 (de) 2005-02-10
NZ527942A (en) 2004-07-30
ZA200204078B (en) 2003-08-22
DK1108787T3 (da) 2005-04-04
CN1433472A (zh) 2003-07-30
CA2392653C (en) 2011-03-29
DE60017234T3 (de) 2009-07-09
AU2557201A (en) 2001-06-04
NO20022500L (no) 2002-07-26
EA006136B1 (ru) 2005-10-27
HK1057236A1 (en) 2004-03-19
NO20022500D0 (no) 2002-05-27
EP1108787A2 (en) 2001-06-20
ES2235770T3 (es) 2005-07-16
EP1103610A1 (en) 2001-05-30
ES2235770T5 (es) 2009-05-01
KR20060107868A (ko) 2006-10-16
EP1108787B2 (en) 2008-12-10
IL149788A (en) 2010-12-30
JP4331432B2 (ja) 2009-09-16
WO2001038362A2 (en) 2001-05-31
SI1108787T2 (sl) 2009-06-30
NO333527B1 (no) 2013-07-01
BRPI0015846B8 (pt) 2021-05-25
EA200200604A1 (ru) 2002-12-26
WO2001038362A3 (en) 2002-02-14
ATE286537T1 (de) 2005-01-15
AU775966B2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
BR0015846A (pt) Método para a produção de um vìrus e/ou proteìnas virais diferentes de adenovìrus ou proteìnas adenovirais, uso de uma célula humana, vìrus ou proteìna viral para uso em uma vacina obtenìvel por meio dos citados métodos e uso, célula humana kit para determinar a atividade de uma protease em uma amostra, uso de uma proteìna viral ou um vìrus, método para concentrar vìrus influenza em condições capazes de, pelo menos em parte,preservar a capacidade de infecção do vìrus, e, vìrus influenza infeccioso ou seus derivados.
AU2002338666B2 (en) Multiplication of viruses in a cell culture
Scheid et al. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai virus
CA2455189C (en) Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture
Follett et al. Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus
ES2536745T3 (es) Métodos de producción de composiciones de vacuna contra la gripe
Wang et al. Establishment and characterization of a new cell line from koi brain (Cyprinus carpio L.)
Famulari et al. High-titer replication of nondefective Sendai virus in MDBK cells
Mazurkova et al. Comparative analysis of reproduction of influenza virus strains in cell lines perspective for the creation of cultural vaccines grown on nutrient medium on the basis of rise flour protein hydrolysate
Choppin et al. The biologic role of host-dependent proteolytic cleavage of a paramyxovirus glycoprotein
Shinagawa et al. Origin of thymidine kinase in the cells infected with infectious canine hepatitis virus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/11/2020